Navigation Links
New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona
Date:11/17/2009

t disease and also have intermittent chest pain, so I visit Dr. Grossman yearly to assess my heart's health. When he offered me the opportunity to take the new Corus CAD test that would detect my risk for coronary artery disease, I jumped at the opportunity to take advantage of the latest technology. When Dr. Grossman walked me through the test's objective results, I immediately felt at ease to know for certain that I am unlikely to have obstructive CAD at this point."

CardioDx, a cardiovascular genomic diagnostics company that developed and launched Corus CAD, has initially launched the test in nine states, including: Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona. Patient access is expected to increase throughout the country in 2010 as Corus CAD's availability expands to additional regions.

About Obstructive Coronary Artery Disease (CAD)

Cardiovascular disease affects tens of millions of Americans each year and is the leading cause of death in the United States. Coronary artery disease (CAD) is a narrowing or blockage of the coronary arteries (the major blood vessels that supply the heart with blood, oxygen and nutrients) that reduces blood flow to the heart muscle. As a result of the blockage, the heart does not get enough oxygenated blood, which can often cause chest pain (angina), shortness of breath and other symptoms. A severe blockage can cause a heart attack (myocardial infarction) or even death; one of every five deaths among Americans is caused by CAD. In 2008, CAD had an estimated direct and indirect cost of over $165 billion.

About Corus CAD

Corus CAD is a clinically validated genomic test that integrates the expression levels of 23 genes and other patient characteristics to assess obstructive CAD. The test is intended to be used in an outpatient setting with clinically stable, non-diabetic patients who present with chest pain or w
'/>"/>

SOURCE Heart & Vascular Center of Arizona
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
2. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
3. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
6. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
7. Curemark CEO Presents at Epigenomics Conference
8. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
9. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
10. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
11. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... AVIV, Israel , July 22, 2014 ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, announced today that ... cleared Galmed,s Investigational New Drug, or IND, application.  Such ... its product candidate, aramchol, in the United ...
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of April 6, 2010 . , ...
... ... , ... ... SILVER SPRING, Md. , March 22 FDA is recommending that healthcare practitioners temporarily suspend use of ...
Cached Medicine Technology:Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 2Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 3Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 4
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... Marc, Ph.D., director of research at the University of ... by the International Society of Eye Research (ISER) as ... 2014 Paul Kayser International Award in Retina Research., The ... has made a significant contribution to the understanding of ... this week at the ISER Biennial Meeting in San ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... As reported on July 17, 2014 by ... name her favorite beauty products, “ Botox , that’s pretty ... “ Botox has changed my life” by halving the ... for her various, daily appearances. “Suddenly my eyelids are ... goo.gl/shmTQM). , “I think that Kelly Ripa’s response to the ...
(Date:7/22/2014)... Autoimmune disorders may share certain pathogenic mechanisms with cancer, ... (GW) researcher Linda Kusner, Ph.D. , published in ... paradigm shifting work shows that the very same inhibitors ... expressed in cells that produce autoimmune diseases. Henry ... at the GW School of Medicine and Health Sciences ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... -- New research finds that compared to mammograms, MRI screenings ... the likelihood that high-risk, underserved women who were specially targeted ... big catch. Researchers were able to reduce the cost of ... the usual $3,500 -- thanks to a grant. As a ...
... Ohio People living in poor neighborhoods are at ... hospital than are people who live in wealthier neighborhoods, ... neighborhoods of differing socioeconomic status and out-of-hospital deaths caused ... 1992 and 2002. In each community, and among whites ...
... Industries LLC announced today the opening of a new expanded ... Ltd. The new facility will double the production capacity ... immune support ingredient. , "We are proud to announce the ... the increasing demand from around the world," said Ken-ichi Kosuna, ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Interventional Radiology Foundation,s Discovery Campaign, which seeks to further ... of discovery, announced a major corporate pledge to that ... St. Jude Medical, has pledged $100,000 and is a ... Medical Foundation strengthens SIR Foundation,s Discovery Campaign as it ...
... fertility-awareness based method of family planning developed by researchers ... Center so effectively meets the needs of users that they ... study finds that women who follow the Standard Days Method, ... it effectively. Results of the large, multi-country study of 1659 ...
Cached Medicine News:Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Living in poor neighborhood a risk factor for out-of-hospital cardiac death 2Health News:Living in poor neighborhood a risk factor for out-of-hospital cardiac death 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2Health News:Long-term effectiveness of new family planning method shown in study 2
Micro suture forceps....
Mini blades....
... M520 OH3 is a smart ... performance available on the market ... stand. The Leica M520 OH3 ... greatest range of movement and ...
Operating microscope with motorized zoom and variable focus up to 405 mm....
Medicine Products: